Companies › Iperboreal Pharma Srl
2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Genitourinary, Cardiovascular; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| XyloCore (Low, Medium, High Strength) Peritoneal dialysis solution containing xylitol (0.7-2.0%), glucose (0.5-1.5%), and L-carn | – | Phase 3 | End Stage Renal Disease | Dec 2026 |
| PolyCore Peritoneal ultrafiltration solution containing polydextrin, L-carnitine, and D-xylitol | – | Phase 1 | Congestive Heart Failure | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03994874 | PolyCore | Phase 1 | Congestive Heart Failure | Cardiovascular | Dec 2026 |
| NCT03994471 | XyloCore (Low, Medium, High Strength) | Phase 3 | End Stage Renal Disease | Genitourinary | Dec 2026 |
No annotated target.
–
Rege Nephro Chengdu Suncadia Medicine Vaderis Therapeutics Addpharma Suzhou Alphamab
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.